{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:54:35Z","timestamp":1781643275690,"version":"3.54.5"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA015083"],"award-info":[{"award-number":["P30 CA015083"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002377"],"award-info":[{"award-number":["UL1TR002377"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2 TR002379"],"award-info":[{"award-number":["KL2 TR002379"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Ophthalmology Practice and Research"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.aopr.2025.11.005","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T17:22:50Z","timestamp":1763659370000},"page":"131-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Novel uveal Melanocyte cell lines display distinct features from uveal melanoma"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9710-4284","authenticated-orcid":false,"given":"Lauren A.","family":"Dalvin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr K.","family":"Kopinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Miley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hien","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha A.","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia M.","family":"Andrews-Pfannkoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie D.","family":"Burr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Armitage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.aopr.2025.11.005_bib1","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.aopr.2025.11.005_bib2","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1136\/bjo.2008.150292","article-title":"The epidemiological challenge of the Most frequent eye cancer: retinoblastoma, an issue of birth and death","volume":"93","author":"Kivel\u00e4","year":"2009","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.aopr.2025.11.005_bib3","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/bjophthalmol-2021-319700","article-title":"Incidence and mortality of uveal melanoma in Australia (1982-2014)","volume":"107","author":"Beasley","year":"2023","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.aopr.2025.11.005_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2017.07.003","article-title":"Integrative analysis identifies four molecular and clinical subsets in uveal melanoma","volume":"32","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.aopr.2025.11.005_bib5","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","year":"2015","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.aopr.2025.11.005_bib6","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/bjophthalmol-2019-314686","article-title":"Nomogram for visual acuity outcome after iodine-125 plaque radiotherapy and prophylactic intravitreal bevacizumab for uveal melanoma in 1131 patients","volume":"104","author":"Dalvin","year":"2020","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.aopr.2025.11.005_bib7","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0161-6420(00)00526-1","article-title":"Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16","volume":"108","author":"Melia","year":"2001","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.aopr.2025.11.005_bib8","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamaophthalmol.2019.5132","article-title":"Visual outcome at 4 years following plaque radiotherapy and prophylactic intravitreal bevacizumab (every 4 months for 2 years) for uveal melanoma: Comparison with nonrandomized historical control individuals","volume":"138","author":"Shields","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.aopr.2025.11.005_bib9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/ICU.0000000000000744","article-title":"Uveal melanoma: laboratory advances and new frontiers in patient care","volume":"32","author":"Xu","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"issue":"6","key":"10.1016\/j.aopr.2025.11.005_bib10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","article-title":"Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis","volume":"29","author":"Rantala","year":"2019","journal-title":"Melanoma Res"},{"issue":"15_suppl","key":"10.1016\/j.aopr.2025.11.005_bib11","doi-asserted-by":"crossref","first-page":"9526","DOI":"10.1200\/JCO.2021.39.15_suppl.9526","article-title":"Overall survival in patients who received checkpoint inhibitors after completing tebentafusp in a phase 3 randomized trial of first-line metastatic uveal melanoma","volume":"39","author":"Orloff","year":"2021","journal-title":"J Clin Oncol"},{"issue":"13 Supplement","key":"10.1016\/j.aopr.2025.11.005_bib12","doi-asserted-by":"crossref","first-page":"CT002","DOI":"10.1158\/1538-7445.AM2021-CT002","article-title":"Abstract CT002: phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma","volume":"81","author":"Piperno-Neumann","year":"2021","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.aopr.2025.11.005_bib13","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.aopr.2025.11.005_bib14","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.22.01705","article-title":"Isolated hepatic perfusion with melphalan for patients with isolated uveal melanoma liver metastases: a multicenter, randomized, open-label, phase III trial (the SCANDIUM trial)","volume":"41","author":"Olofsson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.aopr.2025.11.005_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143426","article-title":"Poor response to checkpoint immunotherapy in uveal melanoma highlights the persistent need for innovative regional therapy approaches to manage liver metastases","volume":"13","author":"Szeligo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.aopr.2025.11.005_bib16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/978-1-62703-727-3_22","article-title":"A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile","volume":"1102","author":"Harbour","year":"2014","journal-title":"Methods Mol Biol"},{"issue":"8","key":"10.1016\/j.aopr.2025.11.005_bib17","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.ophtha.2018.03.011","article-title":"The cancer genome atlas project: an integrated molecular view of uveal melanoma","volume":"125","author":"Jager","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.aopr.2025.11.005_bib18","first-page":"T5","article-title":"Uveal melanoma cell lines: where do they come from? (an American ophthalmological Society Thesis)","volume":"114","author":"Jager","year":"2016","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"13","key":"10.1016\/j.aopr.2025.11.005_bib19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1167\/iovs.65.13.60","article-title":"Novel uveal melanoma patient-derived organoid models recapitulate human disease to support translational research","volume":"65","author":"Dalvin","year":"2024","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.aopr.2025.11.005_bib20","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1600-0749.1987.tb00396.x","article-title":"Normal uveal melanocytes in culture","volume":"1","author":"Hu","year":"1987","journal-title":"Pigment Cell Res"},{"issue":"7","key":"10.1016\/j.aopr.2025.11.005_bib21","first-page":"2210","article-title":"Studies of human uveal melanocytes in vitro: isolation, purification and cultivation of human uveal melanocytes","volume":"34","author":"Hu","year":"1993","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"10","key":"10.1016\/j.aopr.2025.11.005_bib22","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1158\/1535-7163.MCT-19-1013","article-title":"The discovery of SWI\/SNF chromatin remodeling activity as a novel and targetable dependency in uveal melanoma","volume":"19","author":"Rago","year":"2020","journal-title":"Mol Cancer Therapeut"},{"issue":"7","key":"10.1016\/j.aopr.2025.11.005_bib23","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/IAE.0b013e31824d09a8","article-title":"Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases","volume":"32","author":"Shields","year":"2012","journal-title":"Retina"},{"issue":"9","key":"10.1016\/j.aopr.2025.11.005_bib24","doi-asserted-by":"crossref","first-page":"6435","DOI":"10.1167\/iovs.11-7523","article-title":"ATP-sensitive potassium (KATP) channel activation decreases intraocular pressure in the anterior chamber of the eye","volume":"52","author":"Chowdhury","year":"2011","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.aopr.2025.11.005_bib25","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1167\/iovs.15-16449","article-title":"Analysis of circadian rhythm gene expression with reference to diurnal pattern of intraocular pressure in mice","volume":"56","author":"Dalvin","year":"2015","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"20","key":"10.1016\/j.aopr.2025.11.005_bib26","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1158\/0008-5472.CAN-20-0078","article-title":"Genomic and epigenomic landscaping defines new therapeutic targets for adenosquamous carcinoma of the pancreas","volume":"80","author":"Lenkiewicz","year":"2020","journal-title":"Cancer Res"},{"issue":"22","key":"10.1016\/j.aopr.2025.11.005_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.158060","article-title":"Culture media composition influences patient-derived organoid ability to predict therapeutic responses in gastrointestinal cancers","volume":"7","author":"Hogenson","year":"2022","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.aopr.2025.11.005_bib28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nbt.1754","article-title":"Integrative genomics viewer","volume":"29","author":"Robinson","year":"2011","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1016\/j.aopr.2025.11.005_bib29","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/gcc.22424","article-title":"Germline BAP1 alterations in familial uveal melanoma","volume":"56","author":"Rai","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"10.1016\/j.aopr.2025.11.005_bib30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ophtha.2017.07.018","article-title":"Uveal Melanoma nuclear BRCA1-Associated Protein-1 immunoreactivity is an Indicator of metastasis","volume":"125","author":"Szalai","year":"2018","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.aopr.2025.11.005_bib31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000515858","article-title":"BAP1 immunostain status in intraocular Biopsy specimens for uveal Melanoma highly correlates with other prognostic markers","volume":"8","author":"Ida","year":"2022","journal-title":"Ocul Oncol Pathol"},{"issue":"9","key":"10.1016\/j.aopr.2025.11.005_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113132","article-title":"Multi-omics comparison of malignant and normal uveal melanocytes reveals molecular features of uveal melanoma","volume":"42","author":"Gentien","year":"2023","journal-title":"Cell Rep"},{"issue":"8","key":"10.1016\/j.aopr.2025.11.005_bib33","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.molonc.2014.06.004","article-title":"Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target","volume":"8","author":"Amirouchene-Angelozzi","year":"2014","journal-title":"Mol Oncol"},{"issue":"8","key":"10.1016\/j.aopr.2025.11.005_bib34","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1158\/1078-0432.CCR-09-3066","article-title":"Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and\/or metastatic tumors","volume":"16","author":"N\u00e9mati","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.aopr.2025.11.005_bib35","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3525","article-title":"Paired basic amino acid-cleaving enzyme 4 (PCSK6): an emerging new target molecule in Human Melanoma","volume":"100","author":"Weishaupt","year":"2020","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"10.1016\/j.aopr.2025.11.005_bib36","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ceca.2016.09.003","article-title":"Selected GRIN2A mutations in melanoma cause oncogenic effects that can be modulated by extracellular glutamate","volume":"60","author":"D'Mello","year":"2016","journal-title":"Cell Calcium"},{"issue":"9","key":"10.1016\/j.aopr.2025.11.005_bib37","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/jid.2014.190","article-title":"Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation","volume":"134","author":"Prickett","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.aopr.2025.11.005_bib38","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/ng.810","article-title":"Exome sequencing identifies GRIN2A as frequently mutated in melanoma","volume":"43","author":"Wei","year":"2011","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.aopr.2025.11.005_bib39","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/PAS.0b013e31816fd53c","article-title":"Novel role for RGS1 in melanoma progression","volume":"32","author":"Rangel","year":"2008","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.aopr.2025.11.005_bib40","first-page":"2673","article-title":"Critical role for non-GAP function of G\u03b1s in RGS1-mediated promotion of melanoma progression through AKT and ERK phosphorylation","volume":"39","author":"Sun","year":"2018","journal-title":"Oncol Rep"},{"issue":"1","key":"10.1016\/j.aopr.2025.11.005_bib41","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.aopr.2025.11.005_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.581985","article-title":"Bioinformatic analysis identifies potential key genes in the pathogenesis of Melanoma","volume":"10","author":"Han","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.aopr.2025.11.005_bib43","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1515\/med-2020-0190","article-title":"Identification of four genes associated with cutaneous metastatic melanoma","volume":"15","author":"Ji","year":"2020","journal-title":"Open Med"},{"issue":"1","key":"10.1016\/j.aopr.2025.11.005_bib44","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1186\/s12967-023-04476-x","article-title":"Correlation of the tumor escape phenotype with loss of PRELP expression in melanoma","volume":"21","author":"Sch\u00e4fer","year":"2023","journal-title":"J Transl Med"},{"issue":"2","key":"10.1016\/j.aopr.2025.11.005_bib45","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/jso.10245","article-title":"Apolipoprotein D expression in cutaneous malignant melanoma","volume":"83","author":"Miranda","year":"2003","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.aopr.2025.11.005_bib46","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.csbj.2024.02.015","article-title":"Uncovering the potential of APOD as a biomarker in gastric cancer: a retrospective and multi-center study","volume":"23","author":"Wang","year":"2024","journal-title":"Comput Struct Biotechnol J"},{"issue":"1","key":"10.1016\/j.aopr.2025.11.005_bib47","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2022.5155","article-title":"ALDH1A1 overexpression in melanoma cells promotes tumor angiogenesis by activating the IL-8\/Notch signaling cascade","volume":"50","author":"Ciccone","year":"2022","journal-title":"Int J Mol Med"},{"issue":"10","key":"10.1016\/j.aopr.2025.11.005_bib48","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/stem.1193","article-title":"ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets","volume":"30","author":"Luo","year":"2012","journal-title":"Stem Cell"},{"key":"10.1016\/j.aopr.2025.11.005_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116252","article-title":"ALDH1A1 confers resistance to RAF\/MEK inhibitors in melanoma cells by maintaining stemness phenotype and activating PI3K\/AKT signaling","volume":"224","author":"Ciccone","year":"2024","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"10.1016\/j.aopr.2025.11.005_bib50","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s12033-023-00672-8","article-title":"LncRNA HAGLR may aggravate melanoma malignancy via miR-4644\/ASB11 pathway","volume":"65","author":"Luo","year":"2023","journal-title":"Mol Biotechnol"},{"issue":"18","key":"10.1016\/j.aopr.2025.11.005_bib51","article-title":"Knockdown of LncRNA-HAGLR restrains the viability and motility of pancreatic cancer via miR-625-5p\/TAF15 axis in vitro and in vivo","volume":"10","author":"Wang","year":"2024","journal-title":"Heliyon"},{"issue":"13","key":"10.1016\/j.aopr.2025.11.005_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310437","article-title":"TRPM2 channels: a potential therapeutic target in Melanoma?","volume":"24","author":"Foster","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.aopr.2025.11.005_bib53","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2022.5333","article-title":"Antagonism of the transient receptor potential melastatin-2 channel leads to targeted antitumor effects in primary human malignant melanoma cells","volume":"60","author":"McKamey","year":"2022","journal-title":"Int J Oncol"},{"key":"10.1016\/j.aopr.2025.11.005_bib54","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12885-016-2247-8","article-title":"GFRA3 promoter methylation may be associated with decreased postoperative survival in gastric cancer","volume":"16","author":"Eftang","year":"2016","journal-title":"BMC Cancer"},{"issue":"17","key":"10.1016\/j.aopr.2025.11.005_bib55","doi-asserted-by":"crossref","first-page":"23633","DOI":"10.18632\/oncotarget.8054","article-title":"The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma","volume":"7","author":"Amirouchene-Angelozzi","year":"2016","journal-title":"Oncotarget"}],"container-title":["Advances in Ophthalmology Practice and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667376225000666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667376225000666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:10:04Z","timestamp":1781640604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667376225000666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2667376225000666"],"URL":"https:\/\/doi.org\/10.1016\/j.aopr.2025.11.005","relation":{},"ISSN":["2667-3762"],"issn-type":[{"value":"2667-3762","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel uveal Melanocyte cell lines display distinct features from uveal melanoma","name":"articletitle","label":"Article Title"},{"value":"Advances in Ophthalmology Practice and Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aopr.2025.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of Zhejiang University Press.","name":"copyright","label":"Copyright"}]}}